Loading...
India's piperacillin imports from MALTA total $26 across 2 shipments from 1 foreign suppliers. M/S APL SWIFT SERVICES (MALTA) LTD leads with $26 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include AUROBINDO PHARMA LTD. This corridor reflects India's pharmaceutical import demand for piperacillin — a concentrated sourcing relationship with select suppliers from MALTA.
M/S APL SWIFT SERVICES (MALTA) LTD is the leading Piperacillin supplier from MALTA to India, with import value of $26 across 2 shipments. The top 5 suppliers — M/S APL SWIFT SERVICES (MALTA) LTD — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | M/S APL SWIFT SERVICES (MALTA) LTD | $26 | 2 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD | $26 | 2 | 100.0% |
MALTA → India trade corridor intelligence
The Malta to India shipping corridor is currently stable, with no significant port congestion reported at major Indian ports such as Jawaharlal Nehru Port (JNPT), Chennai, and Mundra. Sea freight from Malta to India typically takes approximately 20 days, while air freight takes about 7 days. The exchange rate between the Euro and the Indian Rupee remains favorable for Indian importers, contributing to cost-effective procurement. Freight rates have remained consistent over the past year, ensuring predictable logistics costs for shipments.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing of pharmaceutical products, including antibiotics like Piperacillin. This initiative may impact the volume of finished formulation imports from Malta, as domestic production increases. However, the PLI scheme is expected to complement existing imports rather than replace them, as certain specialized formulations and dosage forms may still be sourced from international suppliers like Malta.
India and Malta maintain a cordial trade relationship, with ongoing discussions to enhance pharmaceutical trade. While there is no formal Free Trade Agreement (FTA) between the two countries, both nations are exploring avenues for mutual recognition of Good Manufacturing Practices (GMP) and other regulatory standards to facilitate smoother trade in pharmaceutical products. These efforts aim to streamline the import process and ensure that products meet the quality expectations of the Indian market.
The landed cost for importing finished Piperacillin formulations from Malta to India includes the following components:
For a shipment with a CIF value of $10,000, the estimated landed cost would be calculated as follows:
Total Landed Cost: $13,941
This estimate provides a comprehensive view of the costs involved in importing finished Piperacillin formulations from Malta to India.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Piperacillin into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the CDSCO's evaluation. For Piperacillin formulations under HS Code 30041090, the manufacturer must demonstrate compliance with Indian Pharmacopoeia standards and provide evidence of market authorization in the country of origin.
Imported batches of Piperacillin formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety in India's climate. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances.
In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing Piperacillin, must obtain import registration and licenses to prevent the sale of unapproved medicines in India. This regulation aims to streamline the import process and ensure that all imported drugs meet Indian quality standards. Additionally, in January 2026, the Indian government introduced Minimum Import Price (MIP)-based restrictions for specific antibiotic formulations, including Piperacillin, to address concerns related to abnormally low-priced imports.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Piperacillin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for manufacturing certain Piperacillin formulations is limited, leading to a reliance on imports to fulfill market needs. The market size for Piperacillin formulations in India is substantial, with a total export market of $88.2 million across 280 exporters to 111 countries.
The Basic Customs Duty (BCD) for finished pharmaceutical formulations containing Piperacillin (HS Code 30041090) is 10%. The Social Welfare Surcharge (SWS) is 10% of the BCD, resulting in an additional 1% duty. The Integrated Goods and Services Tax (IGST) is levied at 12% on the total of the CIF value plus BCD. There are no exemptions or preferential duty rates for imports from Malta.
India sources finished Piperacillin formulations from Malta due to the availability of patented formulations and specialized dosage forms not produced domestically. Malta's pharmaceutical industry is known for high-quality manufacturing standards and compliance with international regulations. While other suppliers like China, Germany, and the United States also export Piperacillin formulations to India, Malta's competitive advantage lies in its adherence to stringent quality controls and the ability to supply unique formulations. Malta's share in India's Piperacillin import market is growing, reflecting its increasing role as a reliable supplier.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Piperacillin formulations from Malta due to the availability of patented formulations and specialized dosage forms not produced domestically. Malta's pharmaceutical industry is known for high-quality manufacturing standards and compliance with international regulations, ensuring the safety and efficacy of the products. Additionally, Malta's strategic location and established trade routes facilitate efficient logistics for timely delivery.
Compared to other origins like China, Germany, and the United States, Malta offers competitive advantages in terms of product quality and regulatory compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Piperacillin suppliers from MALTA to India include M/S APL SWIFT SERVICES (MALTA) LTD. The leading supplier is M/S APL SWIFT SERVICES (MALTA) LTD with import value of $26 USD across 2 shipments. India imported Piperacillin worth $26 USD from MALTA in total across 2 shipments.
India imported Piperacillin worth $26 USD from MALTA across 2 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Piperacillin sourced from MALTA include AUROBINDO PHARMA LTD. The largest buyer is AUROBINDO PHARMA LTD with $26 in imports across 2 shipments.
The total value of Piperacillin imports from MALTA to India is $26 USD, across 2 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists